An ongoing dialogue on HIV/AIDS, infectious diseases,
October 30th, 2024
The Riveting Conclusion of How PCP Became PJP
Before I get back to the saga of Brave New Name — How PCP Became PJP and Why It Matters, allow me to share that I had some trepidation about publishing this thing. A deep dive down a hole with very high-risk for tularemia exposure (see what I did there?), it veered off topic more than […]
October 22nd, 2024
Brave New Name — How PCP Became PJP and Why It Matters
In the pre-E**n M**k era of the site then known at Twitter, I posted a poll about a very important debate in clinical Infectious Diseases: That’s right. Nearly 900 people took the time, energy, and clicks to weigh in on the critical question of what to abbreviate the well-known opportunistic infection in immunocompromised hosts. Fifteen […]
October 8th, 2024
Why We Have Antibiotic Shortages and Price Hikes — And What One Very Enterprising Doctor Did in Response
At the start of our weekly case conference, we get announcements from one of our ID pharmacists. New drug approvals, hospital policies, updated guidelines — that kind of thing. But over the last decade or so, the most common topic they’ll comment on is the latest important antibiotic shortage. For those not in medicine, you […]
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.